glp 1 agonist medicine GLP-1 Drugs from the Gray Market GLP-1 Agonists: A Comprehensive Overview

Distribution of single-nucleotide variants on protein-protein interaction sites and its relationship with minor allele frequency

They are approved only for type 2 diabetes management and, for specific agents like semaglutide (Wegovy) and liraglutide (Saxenda), chronic weight management in adults with obesity or overweight with comorbidities

By improving insulin production, minimizing glucagon secretion, and impacting areas in the brain that control appetite, semaglutide can help reduce hunger and promote feelings of fullness

More users, more demand, and more competition

2023 Ludvik B, Giorgino F, Jodar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial